drugset / Trial / NCT01936909

Interleukin-1 Blockade in Recently Decompensated Heart Failure

NCT01936909

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.

Timeline

Start
2014-02
Primary completion
2016-09-23
Completion
2016-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 100 mg Subcutaneous

Indications